Over the 90-day window ending February 07, 2026, Sagimet Biosciences's three dominant insider ownership positions are held by TenPercentOwner Partners 13, Limited Partnership Nea (3.00Mn shares), TenPercentOwner Enterprise Associates 13 Lp New (3.00Mn shares), TenPercentOwner Pbd Associates, Llc Kpcb (1.90Mn shares).
| Holder | Position | Shares | Report Date |
|---|---|---|---|
| Partners 13, Limited Partnership Nea | 3,000,275 | 31 Jan, 2024 | |
| Enterprise Associates 13 Lp New | 3,000,275 | 31 Jan, 2024 | |
| Pbd Associates, Llc Kpcb | 1,899,475 | 20 Jul, 2023 | |
| Jinzi Jason Wu | 1,654,701 | 20 Jul, 2023 | |
| David Happel | President & Ceo | 689,722 | 23 Jul, 2025 |
| Elizabeth Rozek | Chief Legal & Admin. Officer | 193,581 | 06 Nov, 2025 |
| Beth C Seidenberg | 131,643 | 20 Jul, 2023 | |
| Eduardo Bruno Martins | Chief Medical Officer | 106,936 | 23 Jul, 2025 |
| George Kemble | Executive Chairman | 81,005 | 21 Nov, 2025 |
| Thierry Chauche | Chief Financial Officer | 17,000 | 07 Feb, 2025 |
| Patrick J Kerins | 13,139 | 31 Jan, 2024 | |
| Merdad Parsey | 12,794 | 20 Jul, 2023 | |
| Forest Baskett | 11,300 | 31 Jan, 2024 | |
| Scott D Sandell | 6,997 | 31 Jan, 2024 |
* Please note that the shares above only reflect shares from the fund portfolio and the institutional portfolio. Shares from the personal portfolio are excluded from this Institutional Ownership Page. See these insiders' latest transactions here on Insider Page.
| Transaction Date | Insider Name | Security Class | Transaction Type | Shares Traded | Price | Shares Remaining | Ownership | Code |
|---|---|---|---|---|---|---|---|---|
| 20 Nov, 2025 | George Kemble | Series A Common Stock | D | 37,688 | $7.69 | 81,005 | D | S |
| 04 Nov, 2025 | Elizabeth Rozek | Series A Common Stock | A | 9,855 | $0.00 | 193,581 | D | A |
| 21 Jul, 2025 | David Happel | Series A Common Stock | D | 65,478 | $9.13 | 689,722 | D | S |
| 21 Jul, 2025 | David Happel | - | - | 689,722 | D | |||
| 21 Jul, 2025 | Eduardo Bruno Martins | Series A Common Stock | D | 8,277 | $9.13 | 106,936 | D | S |
| 21 Jul, 2025 | Elizabeth Rozek | Series A Common Stock | D | 10,780 | $9.13 | 183,726 | D | S |
| 06 Feb, 2025 | David Happel | Series A Common Stock | A | 116,000 | $0.00 | 755,200 | D | A |
| 06 Feb, 2025 | Eduardo Bruno Martins | Series A Common Stock | A | 34,000 | $0.00 | 115,213 | D | A |
| 06 Feb, 2025 | Thierry Chauche | - | - | 17,000 | D | |||
| 06 Feb, 2025 | Thierry Chauche | Series A Common Stock | A | 17,000 | $0.00 | 17,000 | D | A |
| 06 Feb, 2025 | Elizabeth Rozek | Series A Common Stock | A | 34,000 | $0.00 | 194,506 | D | A |
| 23 Jul, 2024 | George Kemble | Series A Common Stock | D | 23,625 | $3.17 | 118,693 | D | S |
| 19 Jul, 2024 | Eduardo Bruno Martins | Series A Common Stock | D | 8,357 | $3.10 | 81,213 | D | S |
| 19 Jul, 2024 | George Kemble | - | - | 142,318 | D | |||
| 19 Jul, 2024 | George Kemble | Series A Common Stock | D | 14,062 | $3.10 | 142,318 | D | S |
| 19 Jul, 2024 | Elizabeth Rozek | Series A Common Stock | D | 10,914 | $3.10 | 160,506 | D | S |
| 26 Mar, 2024 | David Happel | Series A Common Stock | A | 12,100 | $5.27 | 639,200 | D | P |
| 26 Mar, 2024 | David Happel | - | - | 639,200 | D | |||
| 29 Jan, 2024 | Patrick J Kerins | - | - | 260,950 | I | |||
| 29 Jan, 2024 | Patrick J Kerins | Series A Common Stock | A | 13,139 | $0.00 | 13,139 | D | J |